Redx Pharma
A drug discovery and development company focused on improving the characteristics of existing drug classes to create best-in-class new drugs in two main areas, cancer and infectious disease.
Launch date
Employees
Market cap
AUD94.3m
Enterprise valuation
AUD103m (Public information from May 2024)
Share price
£0.1497 REDX.L
Company register number 07368089
Macclesfield England (HQ)
Financials
Estimates*
| GBP | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 3.1m | 5.7m | 10.0m | 18.7m | 4.2m | 12.5m | 1.3m |
| % growth | 2308 % | 82 % | 77 % | 86 % | (78 %) | 197 % | (90 %) |
| EBITDA | (5.8m) | (7.6m) | (19.1m) | (15.2m) | (29.2m) | (25.9m) | (49.7m) |
| % EBITDA margin | (186 %) | (134 %) | (190 %) | (81 %) | (696 %) | (207 %) | (3967 %) |
| Profit | 5.8m | (9.2m) | (21.6m) | (18.0m) | (33.2m) | (26.1m) | (49.3m) |
| % profit margin | 186 % | (162 %) | (215 %) | (96 %) | (789 %) | (209 %) | (3938 %) |
| EV / revenue | 3.2x | 17.6x | 21.9x | 8.0x | 20.2x | 4.3x | 77.8x |
| EV / EBITDA | -1.7x | -13.2x | -11.5x | -9.9x | -2.9x | -2.1x | -2.0x |
| R&D budget | 4.2m | 9.9m | 24.4m | 28.6m | 29.1m | - | - |
| R&D % of revenue | 133 % | 175 % | 244 % | 153 % | 693 % | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
£1.9m | Early VC | ||
£4.7m | Grant | ||
* | N/A | - | |
| N/A | $20.5m Valuation: $75.3m -14.7x EV/LTM EBITDA | IPO | |
| N/A | £10.0m | Post IPO Equity | |
$1.0m | Grant | ||
N/A | Acquisition | ||
£22.2m Valuation: £58.1m 18.6x EV/LTM Revenues -10.0x EV/LTM EBITDA | Private Placement VC | ||
£25.7m Valuation: £169m 54.1x EV/LTM Revenues -29.0x EV/LTM EBITDA | Private Placement VC | ||
* | N/A | £35.0m | Post IPO Equity |
* | N/A | Merger | |
* | £14.0m | Post IPO Equity | |
| Total Funding | AUD113m | ||
Related Content
Recent News about Redx Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
